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Abstract 
Epilepsy is a common disease that affects about 1 % of the population. The neurological disease is 
characterised by episodes of neural hyperactivity (seizures) and neural synchronization that can have 
behavioural manifestations such as convulsions. Anti-epileptic drugs (AEDs) can be used for treating 
most cases of epilepsy, but since especially temporal lobe epilepsy (TLE) has proven to be drug 
resistant, there is still a need to develop novel treatment methods. The research towards such new 
treatments requires animal models that mimic the pathology of the human disorder. In this project, 
optogenetics is used in evoking seizure-like afterdischarges (ADs) in anaesthetised mice by 
stimulating the CA1 region of the hippocampus. The mice are transgenic, expressing 
channelrhodopsin 2 – green fluorescent protein (ChR2-GFP) under the Thy1 promoter. An optrode is 
constructed and used to both stimulate with 463 nm light in 10 Hz pulses and to record an 
intracranial electroencephalogram (EEG). The tissue response and amount of ADs that follows a light 
stimulation train is evaluated. Also, spontaneous activity is assessed by calculating the burst 
suppression rate (BSR).  Isoflurane and ketamine anaesthesia is compared and it is concluded that 
ketamine at the dose of 80mg/kg blocks the development of ADs following a stimulation train. On 
the other hand, the isoflurane anesthetised animals developed ADs which seemed to escalate in a 
kindling like manner. 
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Sammanfattning på svenska 
Epilepsi är en vanlig neurologisk sjukdom som drabbar ungefär 1 % av befolkningen. Beroende på 
vilken del i hjärnan som är påverkad så blir manifestationerna av ett anfall olika. Om hyperaktiviteten 
är lokal och inte sprider sig kan patienten bli frånvarande och få automatismer. Generaliserade anfall 
är mer allvarliga och medför ofta stora krampanfall. En mycket vanlig form av epilepsi är 
temporallobsepilepsi (TLE). Denna typ utgår oftast ifrån hippocampus och tenderar att vara 
motståndskraftig mot medicinering. Om fallet är allvarligt övervägs ett kirurgiskt ingrepp där det 
sjuka området avlägsnas, men detta måste noga vägas mot de konsekvenser som en sådan lesion kan 
innebära. Eftersom behandlingen för TLE idag är bristfällig så finns det ett behov av att utveckla nya 
behandlingsmetoder, något som både kräver grundforskning kring epilepsi och innovation. Hjärnan 
är ett mycket komplext organ med multipla celltyper som är kopplade i ett intrikat nätverk. Det är 
idag svårt att återskapa ett ekvivalent system, och därför genomförs forskning i intakt hjärnvävnad. 
Majoriteten av experimenten är dock för farliga för att utsätta människor för, och då det saknas 
alternativ måste försöken göras på djur.  
En djurmodell härmar i något avseende patologin från den mänskliga sjukdomen. Detta 
examensarbete är ämnat att bidra till arbetet med att ta fram en optogenetisk krampmodell. 
Optogenetik är ett relativt nytt verktyg för neurologisk forskning och ger forskare möjlighet att 
påverka specifika nervcellspopulationer med en hög tidsupplösning. Tekniken bygger på att man med 
hjälp av genteknik för in ljuskänsliga protein, opsin, i cellmembranet i vissa specifika nervceller. De 
aktiveras av ett begränsat spektrum av ljus och ändrar flödet av joner genom cellmembranet. 
Effekten på nervcellen varierar beroende på vilken typ av opsin som införts. Opsin kan antingen 
depolarisera eller hyperpolarisera cellmembranet, vilket leder till en initiering eller en inhibering av 
aktionspotentialer. I detta projekt har det depolariserande opsinet Channelrhodopsin 2 (ChR2) 
använts för att skapa hyperaktivitet i hippocampus i genmodifierade möss. Ett stimuleringsprotokoll 
med upprepade ljuspulser användes för att provocera fram epileptisk aktivitet i form av 
efterurladdningar (afterdischarges).  
Djuren är sövda under experimenten, och eftersom sövningsmedlen i viss utsträckning interagerar 
med samma cellulära mekanismer som opsinen gör, så finns det anledning att tro att det finns en 
interaktion. Målet med detta examensarbete är att utröna vilka effekter valet av narkosmedel har på 
den optogenetiska krampmodellen. För att undersöka detta jämfördes två grupper av möss; den ena 
sövd med inhalationsmedlet isoflurane, den andra med det injicerade ketamine/xylazine. För att 
komplettera undersökningen fick även ett djur en falsk stimulering under isoflurane-narkos.  
Efter experimenten utvärderas mängden efterurladdningar och spontan aktivitet. Vissa nya 
analysmetoder fick tas fram för att tackla variabilitet och störningar i EEG inspelningen, bl.a. med 
hjälp av matematiska analysprogram och filterfunktioner. Av resultaten kan man dra slutsatsen att 
ketamine, i den dos som användes i dessa experiment, är ett olämpligt narkosmedel för den 
optogenetiska krampmodellen. Djuren i denna grupp utvecklade inte urladdningar i samma 
utsträckning som de som var sövda med isoflurane. Dessutom så uppkom en mycket kraftig störning i 
EEG inspelningen i ketamindjuren, som kunde härledas till djurens andning. Denna störning 
överskuggade mer eller mindre den intressanta neurala aktiviteten. De djur som var sövda med 
isoflurane uppvisade dock efterurladdningar. Dessa verkade dessutom eskalera under experimentets 
gång, något som skiljer sig från vad som tidigare rapporterats.   
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Abbreviations 
ANN Artificial neural network 
AEDs Anti-epileptic drugs 
BMC Biomedical centre 
BSR Burst suppression rate 
CA Cornus ammonis 
CamKII Ca2+/calmodulin-dependent protein kinases II 
ChR2 Channelrhodopsin 2 
CNS Central nervous system 
EEG Electroencephalogram 
EPSP Excitatory post synaptic potential 
GABA γ-aminobutyric acid  
GFP Green fluorescent protein 
IBE International bureau of epilepsy 
ILAE International league against epilepsy 
i.p. intra peritoneal 
IPSP Inhibitory post synaptic potential 
NpHR Natronomonas Pharaonis Halorhodopsin 
PV Parvalbumin 
RMS Root mean square 
SEM Standard error of the mean 
TLE Temporal lobe epilepsy 
XFP X fluorescent protein 
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1. Introduction 
Epilepsy is a severe disease which can cripple the life of the sufferer, never knowing when a seizure 
may strike. The seizures are often exhausting for the patient and are in many cases dangerous to 
both health and the surroundings. As of today there are many anti-epileptic drugs (AEDs) available, 
although with some significant side effects, such as drowsiness and nausea. Some of the patients 
respond to the pharmacological treatment and can expect to be seizure free. Though, there are some 
types of epilepsy that are more resistant to drugs than others. One of those types, temporal lobe 
epilepsy (TLE), which is emerging from the hippocampus, is the most common form of epilepsy in 
humans [1].  
There are few alternatives to the pharmacological treatment approach. An invasive surgical 
operation removing the focal centre is one, but sometimes the consequences of an operation, such 
as loss of speech or hearing, are not acceptable. There is therefore a need to develop novel methods 
to engage the problem. The development of such new treatments will require studies of the disease 
per se and evaluation of new innovations.  
In order to study complex diseases, such as epilepsy, scientists are utilizing animal models which 
serve to mimic the nature of the disorder. These models express one or many features of a disease 
which can be studied in acute or chronic experiments. In epilepsy studies, a frequently used model is 
the “electrical kindling model” where a rat brain is focally stimulated with an intracranial electrode 
giving repetitive pulses until seizures emerge. As this procedure is repeated, the duration of the 
following seizures increase gradually and the behavioural signs are also elevated. It is argued that this 
model share many features with TLE, if the kindling is performed in the hippocampus [2]. 
This master’s thesis is a part of a project where optogenetics is utilized to refine the TLE kindling 
model. Optogenetics is based on bioengineered ion channels (opsins), originally found in various 
unicellular organisms, which can be expressed in brain cells using different gene techniques. Once 
they are activated by light, they change their permeability to specific ions. The change in 
permeability will result in a net flux of ions that will either hyper- or depolarize the cell. This 
technique is capable of activating or deactivating specific areas and cells in the brain, by exciting or 
inhibiting neurons [3]. Massive activation by exciting neurons is believed to have similar effects on 
the brain as the electrical kindling method has. Previous studies have shown that a train of light 
pulses will be followed by afterdischarges alike those pursuing an electrical kindling protocol [4].  
One major challenge in using optogenetics in-vivo is delivering the light to the tissue and 
simultaneously recording the signals from this stimulated volume. One approach to tackle this is to 
use an optrode, which is an optic fibre fused with a recording electrode. This probe can be inserted 
into the area of interest, in this case the hippocampus, through the skull bone; a procedure that 
requires that the animal is put under anaesthesia.  
Previous work with the optogenetic seizure model in this laboratory has resulted in a hypothesis 
that anaesthetic drugs interact negatively with the development of afterdischarges. Some 
anaesthetics target the same cellular functions as the optogenetics and it is postulated that there 
might be interference. Since the occurrence of afterdischarges in the model is crucial for future TLE 
research applications, it is necessary to maximize the abundance of these disease mimicking 
features. Therefore, the anaesthetic effects on the optogenetic seizure model must be explored. 
By exchanging the previously used anaesthetic isoflurane to a combination of ketamine and 
xylazine, which has a different mechanism of action, we expect to see more afterdischarges 
developing in the animals. 
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2. Aims of the thesis 
This master’s thesis primary objective is to contribute to the work of refining and optimizing the 
optogenetic seizure model, in order to make it an effective tool in epilepsy research. The three 
specific aims with this work are: 
 
 To characterize the optogenetic seizure model, in order to establish if it is possible to predict 
the occurrence of afterdischarges and other electrographic events.  
 
 To explore whether and how the anaesthetic drug isoflurane affects the optogenetic seizure 
model.  
 
 To optimize the procedure in respect to anaesthetic method and optrode position. 
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3. Theory 
This section contains background information that is necessary for understanding the experimental 
procedures and the discussion of the results. Some topics are not used in the methodology, but are 
addressed because they are crucial for the future translation into clinical applications. 
3.1 Epilepsy 
The most used definition of epilepsy is based on a consensus between the international league 
against epilepsy (ILAE) and the international bureau of epilepsy (IBE). It reads as follows: 
 
“An epileptic seizure is a transient occurrence of signs and/or symptoms due to abnormal excessive 
or synchronous neuronal activity in the brain [5].”  
 
“Epilepsy is a disorder of the brain characterized by an enduring predisposition to generate epileptic 
seizures and by the neurobiologic, cognitive, psychological, and social consequences of this condition. 
The definition of epilepsy requires the occurrence of at least one epileptic seizure [5]. “  
 
The massive synchronous activity in the brain during a seizure can be detected when recording an 
electroencephalogram (EEG) (see figure 1). Electrodes are placed on specific locations on the skull 
bone and measure the potentials that arise from the neuronal signalling. When more detailed 
observations are necessary, as in many research applications, the electrodes can be placed 
intracranial directly in the tissue of interest. 
A seizure (ictus) often causes loss of awareness and can be accompanied with behavioural 
manifestations that cause severe exhaustion, such as convulsions. In some cases, the seizure is 
preceded by an aura, where for example a distinct feeling of fear or a strange abdominal sensation 
tells the patient that a seizure is near [6]. The generalized tonic-clonic seizure (grand-mal) is the most 
infamous form of seizure where the patient suffers from massive convulsions. There are also less 
violent forms, such as absence seizures (petit mal) where the patients lose consciousness, that never 
the less disturb the everyday life of the sufferer. In many cases, the sufferers and their relatives are 
also experiencing the indirect effects of the disease such as prohibition to drive vehicles, fear of new 
seizures and incomprehension from employers [7, 8]. 
Figure 1. Intracranial EEG recording from cortex and the hippocampus during an epileptic seizure in a 
rat.  
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Over 40 diseases sort under the above mentioned definitions, all of them classified in respect to 
origin and clinical manifestations [9]. Two main classes of seizures constitute the basis of the 
classification. Generalized epileptic seizures spread rapidly in a bilateral network involving a large part 
of the brain but not necessarily the entire cortex. The onset point and seizure propagation may vary 
from time to time. The other category, the partial epileptic seizures, has the same point of origin 
which spreads the hyperactive signalling along preferred paths. In some cases secondary 
generalization occur where the epileptiform activity spreads to the whole brain [6, 10].  
In the year of 2011, 6301 persons in Sweden were diagnosed with epilepsy in closed care [11], and 
it is estimated that a total of 60000 individuals suffer from the disease [6]. Prevalence in other 
countries varies between 3- 11 / 1000 [12].  
The most common form of epilepsy is the TLE which originates from the mesial temporal limbic 
structures [1]. Even though the precise location of origin is debated there are signs that indicate that 
the hippocampus is closely related to the disease [13]. The seizures of TLE are primarily partial 
complex seizures which often develop into secondary generalizations [1]. These typically have three 
components; an aura, disturbed consciousness and automatisms. The latter means more or less 
uncontrolled motoric activity i.e. lip smacking or belly scratching. As the composition among the 
components varies, the seizure characteristics differ between patients [6]. TLE is often accompanied 
by hippocampal sclerosis and brings a bad prognosis of the patient being seizure free because of its 
resistance to AEDs [1].  
The treatment of epilepsy is dependent on type and severity. Pharmacological compounds, AEDs, 
are the most subscribed and focus on altering the ion transport over the cell membrane, thereby 
affecting the excitability of the neurons. By targeting ion channels such as Na+-channels and GABAA it 
is possible to dampen the hyperactivity that causes seizures by enhancing the inhibitory mechanisms 
in the brain [14].  
Surgical methods are evaluated, if AEDs are not efficient, to conclude whether a focal centre can be 
removed without undesirable effects. In severe and very rare cases, the brain hemispheres are 
separated by cutting the corpus callosum to restrict the spreading of the seizure [15]. Although this 
particular operation is extreme, smaller surgical methods are suggested to be utilized more 
frequently because of the good prognosis of becoming seizure free in some types of epilepsies [1].  
3.1.1 Hippocampus 
The hippocampal formation is located in the temporal lobe and is composed of a couple of 
substructures, one of them being the hippocampus. These structures are considered to be involved 
in the facilitation of memories and spatial orientation [16]. The anatomy of the hippocampus differs 
from other cortical neural structures because of its mostly unidirectional signalling pathways [17]. 
Excitatory inputs enter the entorhinal cortex where it is transmitted to the dentate gyrus through the 
perforant pathway. The axons of the granule cells in the dentate gyrus, called mossy fibres, are then 
connected to pyramidal cells in the CA3 region via the hilus. CA derives from Cornus Ammonis, the 
horn of the Egyptian god Ammon. CA3 cells signal to the CA1 region by the Schaffer collaterals. The 
CA1 projects to the subiculum via the alveus and the pyramidal cells of the subiculum connect again 
to the deep layers of the entorhinal cortex. These connections involving the CA1, CA3 and dendate 
gyrus is called the feed-forward tri-synaptic circuit [18] (see figure 2). 
There are mainly two types of neurons in the hippocampus, pyramidal cells and interneurons. The 
pyramidal cells are in majority and use glutamate as neurotransmitter while the interneurons release 
γ-aminobutyric acid (GABA). These two cell types serve as counterparts; pyramidal cells are 
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excitatory and evoke excitatory post synaptic potentials (EPSP)in target neurons while interneurons 
inhibit activity by inducing inhibitory post synaptic potentials (IPSP)in target neurons [19]. An EPSP 
will depolarise the post synaptic membrane and, if strong enough, initiate an action potential. The 
IPSP, on the other hand, will hyperpolarise the membrane preventing action potentials to initiate 
[16].  
Some argue that the underlying cause of TLE is an imbalance between these inhibitory and 
excitatory mechanisms. However, the opinions of what causes this imbalance differ. One group of 
scientists claim that GABAergic inhibition in fact synchronise the neural network into massive 
epileptiform activity [20]. Another view is that lack of GABAergic inhibition sometimes makes the 
system unable to prevent seizures [21].  
 
 
Figure 2. (A) Coronal Nissl stained slice of a mouse brain. The hippocampus, with the dendate gyrus 
(DG) and cornus ammonis 1 (CA1) region, is marked. Adopted from Allen Institute of Science in 
accordance with their citation policies [22]. Scale bar: 1 mm. (B) ChR2-GFP expression in 
hippocampus. Intense green correlates to high expression. Scale bar: 1 mm. (C) Schematic picture of 
the feed-forward tri-synaptic circuit in the hippocampus.  
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3.2 Optogenetics 
One of the inventors of optogenetics (together with Edward Boyden) Karl Deisseroth defines the 
method as:   
 
“Optogenetics is the combination of optical and genetic methods to achieve gain or loss in function of 
well-defined events in specific cells of living tissue [3].”  
 
The method, which is based on membrane bound light responsive proteins called opsins, has 
developed steadily since invented and was first implemented in neurons in 2005 [23]. Even though 
the technique as such is new, it has been desired for a long time. As early as 1979, the Nobel laureate 
Francis Crick predicted that there would be a need to inactivate one specific cell type without altering 
the functions of others in order to fully interrogate the complexity of the brain [24]. In addition to 
such specificity, a method to interrogate the circuits of the brain should have fast kinetics to provide 
high temporal control of the neural activity.  
Classical neurological methods to manipulate neurons such as electrical stimulation, 
pharmacological compounds and genetic techniques have not yet been able to combine both the cell 
type specificity and the fast kinetics required to exert such precise control of neural circuits. Electrical 
stimulation with electrodes provides the high temporal resolution that is needed to excite or inhibit 
single action potentials in neurons. Though, even if the time resolution is adequate, it is hard to 
achieve specific control of one cell type because of the general electrical influence the electrodes 
have on their immediate surroundings. In the other end, pharmacological methods and genetic 
approaches are able to target specific cell types, but have too slow kinetics to control discrete spiking 
in neurons [25]. Optogenetic methods combine the fast elements from the electric stimulation with 
the high selectivity that is achieved with gene techniques and provide a new approach to interrogate 
and control the brain (see table 1). 
Since optogenetics has proven to be such a powerful tool, it is suggested to be recruited to many 
areas of neurological research. It is for example suggested to be utilized in moderating epilepsy by 
exciting interneurons in the hippocampus [26]. 
 
Table 1: Optogenetic stimulation methods combine high cell specificity with fast kinetics. 
 
3.2.1 Opsins 
The opsins belong to the protein family retinylidene which use retinal as a cofactor. They are 
divided into two subgroups depending on their origin. The archaeal type (Type I) is expressed mainly 
in prokaryotes where they function as ion pumps or contribute to phototaxis. Type II are found in 
higher eukaryotes and work as photoreceptors in eyes [27]. Even though the two groups show 
remarkable similarities they are not phylogenetically related and have developed independently of 
each other [28].  
 
ELECTRIC CHEMICAL / GENETIC OPTOGENETIC 
KINETICS Fast Slow Fast 
SPECIFICITY Low High High 
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The first opsin was found in a microbe called Halobacterium Halobium in 1971 [29]. The protein 
(bacteriorhodopsin) proved to be a proton pump that was activated by light [30]. To this date 
multiple different opsins have been discovered. Their common feature is that they are 7-
transmembrane proteins that form a pocket in which the vitamin A derived chromophore retinal is 
covalently bound [31]. When retinal is bound to the opsin the complex is called rhodopsin and their 
light associated functions are utilized in many organisms, both prokaryotic and eukaryotic. Retinal 
(by chance) proved to be abundant in vertebrae central nervous system (CNS) neurons and is not 
considered to be lacking in optogenetic applications [32].  
It is the cofactor retinal that reacts to light by isomerization. The type I opsins make use of the all-
trans retinal change to 13-cis retinal upon photon interaction (see figure 3). The rhodopsin complex 
then initiates its photocycle which ends with the thermal re-isomerization of the retinal back to its 
ground state [33]. The wavelength which activates the rhodopsin is dependent on the charges 
surrounding the retinal Schiff base (RSB) linkage to the opsin [27].  
 
Figure 3: The light induced isomerization of all-trans retinal to 13-cis retinal. In this illustration, retinal 
is bound to an opsin by the lysine (Lys) linkage.  
 
To this date there are numerous opsins available that have different activation light wavelengths 
and functionality. Most of them function as light activated ion channels or pumps that either 
hyperpolarize or depolarize the cell membrane, but recently G-protein coupled functionality has 
been developed as well (OptoXR) [34].  
The most commonly used opsins are Bacteriorhodopsin (BR), Halorhodopsin and the 
Channelrhodopsin 2 (ChR2). These three membrane bound proteins change the membrane 
permeability of different ions and hence affect the membrane potential in cells. BR is a light driven 
proton pump that is suggested to harvest light energy by building a pH gradient over the membrane 
[30, 31]. ChR2 is a non-selective cation (H+, Ca2+, Na+, K+) channel and will depolarize the membrane 
upon activation. Another type of opsins is hyperpolarising; the Halorhodopsin that is derived from 
the Natronomonas Pharaonis (NpHR) can selectively pump Cl-  into the cytosol preventing action 
potentials to form [35] (see figure 4). It is suggested that this type of opsins could be used in 
supressing epileptic seizures [36]. 
ChR2, derived from the alga Chlamydomonas reinhardtii, is often used when working with 
excitatory optogenetics. This opsin is activated by blue-green light (about 470 nm) and is very fast 
acting. There is roughly a 6 ms latency between light onset to peak amplitude in hippocampal 
neurons [37, 38]. ChR2 is the opsin of choice for the optogenetic seizure model. 
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Figure 4: Schematic illustration of ChR2 and NpHR in the cell membrane. ChR2 is permeable to cations 
and NpHR selectively pumps chloride ions upon light interaction. The two types of opsins react to 
different wavelengths of light.  
3.2.2 The membrane potential 
All living cells depend on the ionic environment both inside and outside the cell to stay alive. 
Regulating the ionic concentrations in the cytosol in respect to the extracellular environment is a 
fundamental and energy consuming task that is required for the maintenance of homeostasis. There 
are multiple types of proteins in the membrane dedicated to the task of controlling the transport of 
ions in and out of the cell. These ion channels can actively (by the consumption of ATP) or passively 
allow passage of specific ion types across the membrane. The specific permeability for each ion is 
dependent on the selectivity of the ion channels. Two forces will act on the ions; diffusion along their 
respective concentration gradient and electric forces due to their charge. These forces combine into 
the electrochemical driving force. If one type of ion is actively transported into the cell, the result will 
be a concentration gradient but also a separation of charge and a resulting electric potential across 
the membrane. This membrane potential is typically around -60 to -70 mV at resting state in 
neurons.  
The Goldman equation describes the equilibrium potential Em over the membrane.  
 
   
  
 
  
  [ 
 ]       [  
 ]       [  
 ]   
  [  ]      [   ]      [   ]  
 
 
This equation considers concentration of each ion [X] as well as the permeability P and also the 
temperature T, the ideal gas constant R and the Faradays constant F. If divalent ions such as calcium 
is included, the equation gets a bit more complicated [39], but in the case of the resting membrane 
potential calcium is of little significance due to the low permeability.  
The ions of interest are mainly Na+, K+, and Cl-, each having special roles to play in the functions of 
the neuron. The opsins in optogenetics momentarily change the permeability for one or a set of ions 
upon activation. This will result in a flow of ions across the membrane and hence a shift in membrane 
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potential. Generally, an increase in cation permeability will result in a depolarisation and an increase 
in Cl- permeability will hyperpolarise the cell [16].  
3.3 Genetic techniques 
The opsin is introduced to the cells of interest by gene techniques. Transgenic animals (the majority 
being mouse models) which are expressing opsins in certain brain areas are available, supplying 
scientists with a flexible tool for various experiments [35]. A transgenic animal is generated by e.g. 
pronuclear injection where fertilized mice eggs are injected with DNA coding for a specific protein 
[40]. 
Another option is to deliver the genes in-vivo using viral vectors. This method is crucial for future 
optogenetic clinical applications. Virus vectors such as lentivirus (LV) and adeno-associated virus 
(AAV) have been used for introducing both excitatory and inhibitory opsins to in-vivo tissue [25]. The 
virus vector is injected in the brain area of interest and subsequently infects a large portion of the 
cells in the vicinity of the injection. The specificity is achieved by using genetic promoters known to 
be expressed by the target cell type alone.  
One of the most promising virus vectors for gene therapy in neurological diseases is the AAV [41]. It 
is capable of invading both dividing and non-dividing cells, which is of essence since most cells of 
interest for neurological applications are in a post mitotic state. AAV also achieves robust expression 
for long periods of time without pathogenicity [41-43]. The possibility to manufacture large amounts 
of purified vectors without contamination of wild type AAV also adds to the suitability of using AAVs 
in clinical applications [44].  
A typical transgene involves a promoter that regulates the expression, a functional gene and a 
reporter. GFP is a commonly used reporter, that will help to confirm the expression during or after 
the experiment (see figure 5). 
 
Figure 5: Schematic illustration of a simple genetic construct of an AAV vector. The Inverted Terminal 
Repeat (ITR) sequences related to the AAV are flanking the construct. A promoter serves to regulate 
the expression, followed by the opsin coupled to a reporter. 
3.3.1 Promoters 
Gene expression is regulated by genetic sequences preceding the gene that codes for a protein. 
These parts are called promoters and work as locks for expressing proteins. To unlock the gene, 
transcriptions factors need to bind to the promoter. Then the transcription into mRNA can begin. 
What specifies a cell type is its sets of transcription factors that regulates the gene expression, since 
the entire genome is present in each cell. The amount of expression is regulated by the number of 
transcription factors dedicated to one promoter [45].  
The promoters are used to target a specific cell type with gene therapy. There are neuronal 
populations that alone express one specific type of protein. The promoter of such protein can then 
be used preceding a transgene in a vector. Expression of this transgene will then be directed to only 
the cell type of interest even though the virus infects all cells.  
There are numerous known promoters that can be used to target different types of neurons. For 
example, the Ca2+ / calmodulin-dependent protein kinase II α (CaMKII α) has been used to target 
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excitatory pyramidal neurons [46] and the Parvalbumin (PV) promoter can be used to specify the 
expression to a certain class of interneurons [47].  
3.3.2 The Thy1 promoter 
Another promoter considered to target neurons is the Thy1 promoter. It regulates the Thy1 protein 
which is an immunoglobulin expressed on the surface of projection neurons and thymocytes [48]. 
The use of the promoter results in random expression in neurons in general which varies depending 
on the transgenic line [49]. One research group reported Thy1 driven XFP (X Fluorescent Protein) 
expression in hippocampal pyramidal cells in transgenic mouse lines [48]. These lines were created 
by injecting fertilized oocytes with gel purified DNA. Based on these findings the Thy1 promoter was 
successfully utilized to drive expression of ChR2-GFP in transgenic mice for optogenetic applications 
[50]. Expression was found to be prominent in many areas of the brain, including the hippocampal 
CA1 and CA3 region [37]. These mice were founders to the ones used in this project.  
3.4 Animals 
Some experiments that are necessary to gain a deeper insight into the pathology of epilepsy require 
the use of invasive methods or the administration of dangerous chemicals. Since it is not acceptable 
to subject humans to these trials, it is considered necessary to conduct animal experiments.  
Mice are relatively easy to manipulate genetically. By knocking in or out genes, one can make the 
mouse mimic the pathological state of a disease. Therefore, there are numerous models available 
that can be applied to research in a wide range of diseases. As mentioned earlier, for research in 
optogenetics, mice can be genetically modified to express opsins in all or a specific subset of 
neurons. These genes are often coupled to a reporter gene, i.e. GFP, to make it possible to track 
where the opsins are expressed. The use of transgenic animals along with the possibility to cross 
different stains supplies the scientists with an extensive optogenetic toolbox.  
All animal experiments in Sweden are regulated by Jordbruksverket and have to be approved by an 
ethical committee before they are performed.  
3.4.1 Epilepsy Models 
There are multiple animal models used in epilepsy research. They all strive to mimic some feature of 
the human condition and are used both for basic research of the pathology and in the development 
of pharmacological agents to treat the disease. There are basically two types of epilepsy animal 
models. In the first, previously healthy animals can be made to acquire epilepsy by some treatment. 
Such treatments could be based on chemical compounds or electrical stimulation. The second type of 
models are genetically predisposed to develop the disease [2].  
A frequently used chemically induced model utilizes the excitotoxic kainic acid (KA) to produce 
seizures of different severity and a seizure focus. The compound, which has a structural similarity to 
glutamate and interact with the kainate receptor, can be injected by a thin glass capillary into a 
specific brain region, i.e. the hippocampus. After a couple of minutes, it will produce status 
epilepticus (SE), a state of continuous seizures. This initial brain insult will, after a latency period, 
develop into both behavioural and electrographic seizures that arise spontaneously and reassemble 
those of TLE. In addition to the seizures, lesions and sclerosis are also induced by the injection [2, 51].  
Another way to develop epilepsy in animals is to use electrical stimulation in a process called 
kindling. Electrodes stimulate the tissue electrically, preferably in the hippocampus or amygdala. 
Stimulations are short and repeated according to a schedule. The behavioural manifestations 
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following such stimulations will increase in both magnitude and length as the stimulations progress 
[52]. Electrographically, a stimulation is followed by afterdischarges, an EEG pattern that share 
similarities with TLE seizures. One problem with electrical kindling is the inability to record the neural 
signals during a stimulation since the provoked currents override the endogenous signals [2].  
An optogenetic seizure model would solve the problem of acquiring recordings from the tissue 
during and immediately following stimulation, but would also provide the option of targeting specific 
cell types in a much more restricted volume than the electrical kindling does. Current research show 
that an optogenetically induced spike train is followed by similar afterdischarges as with electrical 
stimulation (see figure 6). However, no increase in afterdischarge duration or seizure severity (no 
kindling effect) has been reported [4].  
 
Figure 6: Optogenetically induced afterdischarges. The neural signalling is initially synchronised with 
the light stimulation. When the stimulation train comes to an end, the tissue continues to be 
activated in a fashion similar to an epileptic seizure.  Adopted from (Osawa, 2013) [4] in accordance 
with PLOSone copyright. 
3.5 Drugs 
The experiments in this project are performed with the animals under anaesthesia for mainly two 
reasons; to enable insertion of the optrode into the hippocampus and to lessen the suffering of the 
animal. In this master’s thesis two types of anaesthesia are compared to see if there are any effects 
on the optogenetic seizure model. The compounds involved with the anaesthesia are presented 
below.  
3.5.1 Ketamine / Xylazine 
Ketamine is a drug used for anaesthetic and analgesic purposes in both humans and animals, 
although administration in humans usually is restricted to cases of emergency where breathing 
depression must be avoided. Though, there are cases where ketamine also has proven to terminate 
SE [53]. The drug acts on the glutamatergic NMDA receptor as a non-competitive antagonist which 
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produces a state of dissociative anaesthesia where the patient is relieved of pain but appear to be 
awake [14, 54]. The potency of ketamine varies between species. Mice need larger doses to achieve 
satisfactory anaesthesia, at which levels severe breathing deprivation may be fatal. Therefore 
ketamine is often combined with another sedative such as Xylazine in order to achieve therapeutic 
effects at lower doses [55].  
Xylazine is not administered to humans, but is used for veterinarian purposes only. It is an α2-
adrenergic receptor agonist which causes sympatholytic effects, such as lowering of blood pressure 
and sedation, due to decreased sympathetic outflow from CNS to the PNS [14]. Xylazine is suitable 
for combining with ketamine in order to achieve surgical anaesthesia [56]. An i.p. administration of 
80 mg/kg ketamine and 15 mg/kg xylazine is expected to result in 15-30 minutes of surgical grade 
anaesthesia and will cause sedation for 1 – 2 h [57]. 
3.5.2 Isoflurane 
Isoflurane is a general inhaled anaesthesia that is frequently used in veterinarian surgery. It is used 
to keep the animal unconscious and is often combined with a local analgesic compound. One 
considerable side effect is the breathing depression it causes at high doses. 
The isoflurane mechanism of action is still debated. The lipid soluble nature of the drug suggests 
that the compound is incorporated into the lipid bilayers of the cell where it may interact and change 
the properties of multiple receptors [14]. In general it is hypothesized that it enhances the function 
of inhibitory receptors such as GABA and glycine receptors and supress the exciting glutamate, 
nicotinic acetylcholine and serotonin receptors [58]. In addition to inducing anaesthesia isoflurane is 
used for treating refractory SE [59]. Isoflurane is fast-acting compared to injected anaesthetics; 
recovery time in mice is reported to be 6.9 ± 3.6 minutes [60].  
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4. Methodology 
4.1 The animals 
The experiments were performed acutely in transgenic male mice. These were 4-6 month old and 
bread in the Lund Biomedical Centre (BMC) facility to hetrozygotically express Thy1-ChR2-GFP. The 
founder lines were originally bought from The Jackson Laboratory. All animals had access to food and 
water ad libitum. This project carried the permit number M206-12 and followed guidelines according 
to Swedish Animal Welfare Agency regulations. 
Two groups of animals were examined; one group was anesthetised with isoflurane only and one 
group were given a ketamine/xylazine combination just before engaging the stimulation trains. In 
addition to the two main groups, one animal had sham stimulations under isoflurane anaesthesia 
(see table 2). 
 
Table 2. The anaesthetic drug, stimulation light wavelength and number of animals in the 
experimental groups. The sham stimulated animal is included for comparison.  
Group 
Anaesthesia Light wavelength Nr. of animals 
Isoflurane Isoflurane 463 nm (in range) 5 
Ketamine Ketamine/Xylazine 463 nm (in range) 4 
Sham animal Isoflurane 593 nm (out of range) 1 
 
4.2 Optogenetic stimulation of hippocampus 
Optrodes, consisting of an optical fibre and an electrode were inserted in the hippocampus of the 
mice brain using stereotaxic surgery. A blue 463 nm LED light was guided through the optical fibre to 
activate the ChR2 expressed in the tissue. The electrophysiological response was measured via the 
electrode.  
4.2.1 Construction of optrode 
The optrode was constructed out of a 200 µm in diameter thick optic fibre and a coated 1 MΩ 
tungsten electrode. The optic fibre was used as a fundament for the construct in order to stabilize 
the optrode. Onto the optic fibre, the electrode was super-glued using a compound based on 
cyanoacrylate. The glue was applied evenly along the optrode, covering the entire surface leaving 
only the outermost tip of the electrode and fibre. In addition to fixing the electrode to the fibre, two 
purposes were served by the glue coat. It helped to smooth the surface of the optrode, with the aim 
of decreasing the trauma to the tissue upon insertion. Also, since the glue is an insulator, it improves 
the insulation and protects the electrode coating from damages (see figure 7).  
The sharp tip of the electrode was placed 0.5 mm below the flat end of the optical fibre. This 
arrangement is necessary to ensure that the evaluated tissue is adequately illuminated and will 
respond the optical stimulation. Only the outermost tip of the electrode is in electrical contact with 
the environment, which increases the resistance and narrows the measured volume enabling 
enhanced spatial resolution of the measurement. The high resistance make it possible to measure 
the activity from single neurons.  
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Figure 7. (A) Schematic picture of the optrode tip. The electrode and optic fibre is covered by layer 
consisting of cyanoacrylate glue. (B) The stereotaxic frame with ear bars and nose clamp. The 
optrodes position in the stereotaxic frame is indicated with an arrow. 
4.2.2 Insertion of the optrode 
The optrode was inserted in the hippocampus with the help of a stereotaxic frame to ensure robust 
localization. The mouse skull was firmly attached to the base of the frame using ear-bars and a nose 
clamp. Calibration points for the coordinates of the medial to lateral (ML, x-axes) and the rostral to 
caudal (RC, y-axes) originated from bregma. The dorsal to ventral (DV, z-axes) was measured from 
the dura. The coordinates were AP: -3.5, ML: -3.5 and DV ranging from – 3.0 to – 3.4 depending on 
the amplitude of the tissue response. These coordinate correlates to the CA1 region of the 
hippocampus. 
After localizing the ML and RC coordinates for penetration, a hole in the skull bone was made using 
an electric drill.  To prevent the dura from being dragged along into the brain tissue, it was carefully 
removed with a needle when the cortex was visible. The ground electrode was placed below the skin 
in the neck of the animal. 
A hydraulic micromanipulator was utilized to control the submersion of the optrode in steps of 0.1 
mm every other minute until the desired depth was reached. The response from the tissue was 
evaluated by each step by the use of two test pulses of light (duration 0.3s, 0.2 Hz).  
4.2.3 Measurement setup 
The experimental setup was based on the PowerLab hardware (PowerLab 4/35, AD Instruments) 
which served as a potentiometer with high resolution. The signal from the tissue was first passed 
through a preamplifier (DP-311 Differential Amplifier, Warner Instruments) which increased the 
signal amplitude 10 times. Next, the PowerLab hardware digitalized the signal and relayed it via an 
USB-cable to the PowerLab software in a laptop computer where it was recorded. 
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The PowerLab and the LabChart software were also used to control the light stimulation. The 
output from the PowerLab was triggered by a collection of stimulation macros (automatic protocols) 
in the software. One channel was reserved to record these output signals in time correlation to the 
tissue response. The output from the PowerLab, in turn, was connected to the power source 
controlling the stimulation LED. This setup enabled setting the duration and frequency of the pulses 
by macro control from the software. Light intensity was altered by changing the output power on the 
LED power source.  
The stereotaxic frame and all incoming cables were housed in a 1 m3 grounded faradays cage to 
minimize the noise (see figure 8). 
 
Figure 8. (A) Schematic illustration of the experimental setup. The PowerLab control both the 
recording and the light stimulation. (B)The experimental setup was enclosed in a faradays cage to 
minimize noise. 
4.2.4 Stimulation protocol 
The light stimulation of the tissue was controlled by macros in the LabChart software. These macros 
independently engaged stimulation trains at predetermined time intervals. A train had a 20 second 
duration and contained 5 ms light pulses fired at a rate of 10 Hz. These trains were activated once 
every 5 minutes. The amount of trains was 30 at a minimum, but the number was increased if the 
animal showed potential of developing more afterdischarges. The entire procedure lasted typically 
for 4 h. including the pre stimulation surgery. 
Stimulations were performed by a blue LED light (UHP-LED-460, Prizmatix) emitting a wavelength of 
463 nm which is within the activation range of the ChR2. The output effect from the optrode tip was 
measured with an optical power meter (Newport, Optical Power Meter 1916-C) and calibrated to 
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hold 2.3 mW which would yield a power of 75 mW / (µm)2. Too high output power would damage 
the tissue because of heating [61].  
Also, one animal was sham stimulated with laser (CrystalLaser, GLC-025-593) holding a wavelength 
of 593 nm, which is outside the ChR2 activation range (see figure 9). 
 
Figure 9: The LED emission spectra and ChR2 activation spectra overlaps sufficiently. The 593 laser, on 
the other hand, will not activate the ChR2. 
4.2.5 Anaesthesia 
The primary anaesthesia was isoflurane administered by an automatic pump (410 Anaesthesia Unit, 
Univentor). For induction, a chamber was filled with a 5% partial pressure of isoflurane. When the 
animal was asleep it was transferred to the stereotaxic frame where a tube connected to the 
anaesthetic pump was located in the close proximity of the nose. Anaesthesia was maintained with a 
dose of 0.7 -2.0 % isoflurane partial pressure and was frequently adjusted to the appropriate level. 
Paw withdrawal response and breathing patterns were checked to approximate the anaesthetic level 
of the animal.  
For the isoflurane group, isoflurane anaesthesia was maintained during the entire experiment. In 
the ketamine group, the isoflurane anaesthesia was exchanged to ketamine/xylazine after the initial 
surgery and optrode implantation was finished. When switching to the ketamine/xylazine 
anaesthesia, a combined dose of 80 mg/kg ketamine and 15 mg/kg xylazine was administered i.p. 
just before the isoflurane pump was turned off. A booster dose of only ketamine (80 mg/kg) was 
administered after approximately 1.5 h. 
In order to support the animal body temperature, the experiment was performed with the animal 
lying on a heating pad. The pad lost temperature after about 1.5 h and had to be replaced with a new 
one. 
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4.3 Histological analysis 
Immediately following the experiment, after a large euthanasic i.p. injection of sodium 
pentobarbital, the mice were perfused with 0.9% saline followed by 4 % paraformaldehyde (PFA). 
The brain was retrieved and put in PFA for 24h. Next, the brain was transferred to a solution of 20 % 
sucrose for another 24 h incubation. 30 µm slices were cut by freezing the brain with dry ice and 
placing it in a microtome. Four series were obtained each containing about 30 slices. One of the 
series were mounted onto hydrophobic microscopy glass and fixed by DABCO solution with added 
Höchst staining before covering with a cover glass. The other samples were stored at -20°C.  
The first brains were cut using coronal slices but later horizontal slices were used because of the 
higher probability of covering the entire lesion. 
The slices were examined in a microscope (BX61, Olympus), looking at the lesion created by the 
optrode. Blue light was used to excite the GFP in order to look at the ChR2-GFP expression and UV 
light was used to visualise the Höchst stained nuclei.  The actual location of the optrode tip was 
determined by comparison to the mouse brain atlas [62].  
4.4 Data evaluation 
The analysis of the recorded data was performed in LabChart, MatLab and MS Excel. 
Values are presented as: mean (1 s.d.) throughout the paper and differences considered significant 
if p < 0.05. 
4.4.1 Afterdischarge detection 
Because of the variability and fluctuations of the data, a method to track the development of 
afterdischarges was designed. The method utilizes filtering functions and mathematical algorithms in 
the LabChart software. First, the recording from the hippocampus was band-pass filtered between 2 
– 250 Hz and notch filtered for 50 Hz. Subsequently the root mean square (RMS) value of each 10 
second period immediately following the stimulation trains was calculated. This value was then 
compared to an artifact free, 10 second long, period preceding each stimulation by calculating an 
activity ratio.  
                
               
                
 
The activity ratio will be larger than 1 if the post stimulation activity exceeds the pre stimulation 
activity. In case of an afterdischarge, the value will be much larger than 1. 
The RMS is calculated by: 
     √
 
 
(  
    
      
 ) 
where n is the number of data points and x are the values. The equation will return an estimate of 
the deviation magnitude of the data in relation to a zero baseline. Because of the band-pass filtering, 
the EEG is oscillating around 0. 
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4.4.2 Burst suppression rate 
A common EEG pattern that emerges when measuring the brain activity in an anaesthetised brain is 
the burst suppression rate (BSR). The pattern is comprised of bursts of activity separated with an 
isoelectric EEG (flat line). This pattern is observed in heavily sedated patients and correlates to some 
extent to the level of isoflurane anaesthesia, which has been shown in rats [63].  
A short algorithm in MatLab was used to detect activity above a threshold of 0.25 mV and to 
calculate the BSR (see figure 10). If the threshold was exceeded, 350 ms of activity is noted. The 
duration is prolonged if there are more peaks following the first (see figure 11). The BSR can then be 
calculated as the percentage of time spent in isoelectric state. 
 
    (   )
              
      
 
 
where        is the duration of the analysed time and         is the cumulated time spent in bursting 
state. 
Figure 10: MatLab algorithm for detecting the periods with bursts from an EEG recording. 
  
last = 0;  %The index of the last detected peak 
burst = [];  %Vector with detected activity 
eeg;  %The EEG data with 1 ms resolution 
t = 0.00025;  %Threshold for burst detection (V) 
step = 350;  %Time reserved to count as active (ms) 
 
for i = 1:length(eeg) 
    if (eeg(i) < -t || eeg(i) > t); 
        burst(i:i+step) = 1; 
        last = i; 
    else if (i - last) > step 
            burst(i) = 0; 
        end 
    end 
end 
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5. Results 
This section first addresses the direct tissue response from the light stimulations. Secondly, events 
that occur outside the stimulation periods are presented. Finally, there is a section dealing with the 
histologic analysis following the experiments. 
5.1 Test pulses 
Stimulating the Thy1ChR2 mice with 463 nm LED light immediately evoked a response from the 
tissue in both the isoflurane and ketamine group. A 300 ms light pulse resulted in a fast spike at the 
beginning, followed by a slight decrease in potential to a level that was maintained during the light 
pulse (see figure 11). The amplitude of the spike varied as the optrode was lowered into the tissue.  
The averaged response potential, just before the first train stimulations, was -4,2 (1.0) mV (n= 9) 
considering the total of the animals. There was no difference between the groups (p = 0.06, two-
tailed unpaired Student’s t-test, see table 3). No response could be seen in the sham stimulated (593 
nm) animal. 
 
Figure 11: The response to two 300 ms long consecutive light stimulations. The light pulses are 
indicated by the blue bars and the EEG recording with a red trace. There is a -4.5 mV peak potential 
upon stimulation. 
 
Table 3: The response from the test pulses. 
Group Response [mean (1 s.d.)] (mV) 
Isoflurane             n=5 
-3.68 (0.86) 
Ketamine              n=4 
-4.9 (0.75)                
Total                      n=9 
-4.2 (1.0) 
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5.2 Stimulation train 
A 20 second long train of 5 ms pulses in 10 Hz resulted in spikes corresponding to the stimuli 
frequency. The amplitude of the spikes were initially large, starting at the same level as the 300 ms 
stimulations, and then decayed and stabilized at a level corresponding to about half of the initial 
value (see figure 12). 
 
 
Figure 12. (A) A intra hippocampal recording during a spike train stimulation with the initial spike 
indicated by an arrow. The tissue responded in phase with the stimulations but decreased in 
amplitude at the end of the train. (B) An enlargement of the area in the black rectangle in figure 13A. 
A small amplitude 50 Hz oscillation superimposed on the spikes is visible. 
 
The amplitude of the initial spike in the stimulation trains changed during the experiment (see 
figure 13). The voltage values rise and fall in a continuous manner even though the general trend 
seems to be that the amplitude decrease with the number of stimulations.  
The decrease was estimated by averaging the amplitude of the initial spikes from two periods of the 
experiment; stimulation number 1-5 and number 25-29. The values from these calculations were 
B 
A 
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then averaged for the two trial groups (see figure 14). There is a significant decrease when looking at 
the total of the animals (paired Student’s t-test, n=8) even though there is no significance within or 
between the trial groups (unpaired Students t-test, n = 5 isoflurane, n = 3 ketamine). The decrease in 
amplitude was 0.78 (0.73) mV when considering all of the animals. One animal (#K4) was excluded 
from the ketamine group due to corrupt data. 
 
Figure 13. The amplitude of the initial spike in a stimulation train. The level of the amplitude differs 
between animals and there is a general decrease in amplitude following multiple stimulations. The 
compared periods (stim. nr. 1-5 and 25-29) are marked in grey. 
 
Figure 14. The averaged amplitude of the initial spikes from 5 stimulations in the isoflurane group, the 
ketamine group and the total of the animals. Two periods are compared; stim. nr. 1-5 and nr. 25-29. 
There is a significant difference between the two periods when considering all of the animas. The 
error bars indicate 1 standard error of the mean (SEM). 
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5.3 Afterdischarges 
At some occasions, especially in the second half of the experiment, the stimulations could be 
followed by self-sustained repetitive discharges. They tended to first appear alone and then to 
increase in number, in some animals peaking at a total number of ten. Although the appearance and 
form of the afterdischarges differed between the animals they all appeared within 15 seconds 
following a stimulation train (see figure 15). 
Figure 15: Typical afterdischarges following a stimulation train in an isoflurane anesthetized animal. 
Light pulses are indicated with blue bars. 
 
The evaluation method based on the RMS values was used to measure the afterdischarge activity 
ratio. In most animals the activity ratio was lower than 1 following the first trains, indicating a 
depression of neural activity after stimulation. In the isoflurane anesthetised animals, this period of 
supressed neural activity post stimulation, seemed to cease after about 25 stimulations and instead 
afterdischarges tended to appear in varying amount. The ketamine animals, on the other hand, did 
not develop afterdischarges.  
The values were fluctuating within the single animal even though there seemed to be an underlying 
continuous mechanism that gradually increased the amount of afterdischarges. In figure 16, one 
isoflurane, one ketamine and the sham stimulated animal are presented. The isoflurane animal 
showed low activity in the beginning and then gradually began to develop afterdischarges around 
stimulation 20. In the ketamine animal, no afterdischarges could be detected, even though there are 
two values indicating an elevated activity. The sham stimulated animal was fluctuating around the 
value of 1. 
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Figure 16: Afterdischarge activity ratio in three animals. The isoflurane animal (#5) develops 
afterdischarges after stimulation nr. 20. The ketamine animal (#1) does not have any afterdischarges. 
The animal with the off-range wavelength sham stimulations varies around 1. 
 
As indicated by figure 16, the start values of the individuals differed. The isoflurane animal showed 
more activity depression following stimulation than the ketamine and sham stimulated animal during 
the 5 first stimulations. Since the start level varies in between animals it is also interesting to 
evaluate the relative development of the activity ratio in each animal. The relative development was 
calculated by dividing all the values with an average of the first 5 stimulations. This procedure 
normalised the groups and made it possible to compare them by average and standard deviation. 
The result is presented in figure 17. 
Figure 17: The averaged relative activity ratio in the isoflurane and ketamine group. (isoflurane n = 5, 
ketamine n = 4). The isoflurane animals show a rise in activity with a large divergence in the data. 
There is no indication of an increased afterdischarge activity in the ketamine animals. The sham 
stimulated animal is included for comparison. Error bars indicate 1 SEM. 
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Reviewing figure 17, it is clear, that the ketamine animals do not show an increase in activity ratio 
following the stimulations, meaning that no afterdischarges did emerge. The isoflurane anesthetised 
animals, on the other hand, begin to develop afterdischarges around the 20th stimulation but the 
values are variable. The sham stimulated animal fluctuates around 1. 
Because of the low number of animals used in this study, it is hard to show any significant 
difference considering only one stimulation number. Though, if the values are gathered into bins of 5 
stimulation events, a significant difference between the isoflurane and ketamine group can be 
showed in bin 16-20, 21-25, 26-30, 31-35 and 36-40 (unpaired Student’s t-test, see table 4). In 
addition to the difference between the trial groups, there is a significant increase between the 
isoflurane bin 16-20 and 36-40 (see figure 18) (paired Student’s t-test, see table 4). 
 
Figure 18: The relative activity ratio gathered into bins of 5 stimulations. The isoflurane group show 
an increase in activity following stimulation 16, and the ketamine group remains at a level around 1. 
There is a significant difference between the two trial groups, and also within the isoflurane group, as 
indicated by asterisks. 
 
Table 4: The number (n) of measurement points used for the Student’s t-test in figure 18. 
Bin 1-5 6-10 11-15 16-20 21-25 26-30 31-35 36-40 
Isoflurane 25 25 
25 25 25 25 25 25 
Ketamine 20 20 
19 19 20 19 16 5 
 
As there seem to be some correlation between the number of stimulations and the occurrence of 
afterdischarges in the isoflurane group, a Pearson’s test was performed (see table 5). The test show 
significant linear correlation in 4 out of 5 animals. 
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Table 5: Result from the Pearson’s correlation test comparing the number of stimulations with the 
activity ratio. The result indicates a linear correlation in 4 out of 5 isoflurane animals. 
Animal 
R R2 p 
Isoflurane 1 0,657 0,432 * 
Isoflurane 2 0,831 0,691 * 
Isoflurane 3 0,601 0,361 * 
Isoflurane 4 0,143 0,021 NS 
Isoflurane 5 0,632 0,400 * 
5.4 Spontaneous events 
In addition to afterdischarges there were larger events on the recording that appeared 
spontaneously without any common rhythm (see figure 19). These events occurred in varying 
amount in all animals and differed widely in duration. The abundance of these events rose and fell 
throughout the experiment and they were in some animals dominating the recording. Spontaneous 
discharges were seldom detected immediately after a stimulation train. 
 
Figure 19. A typical spontaneous event, in this case occurring just before a stimulation train. 
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The amount of spontaneous activity can be appreciated by calculating the BSR. Because of 
ubiquitous breathing artifacts in the ketamine group no BSR for these could be calculated. Below, in 
figure 20, 3 animals representing standard cases are presented. The ‘Isoflurane animal 1’ has a BSR 
above 95% during the entire procedure. Both the ‘Isoflurane animal 2’ and the sham stimulated 
animal have a period with more spontaneous activity in the middle of the experiment.  
 
Figure 20. The BSR (presented as the percentage of time spent in isoelectric EEG) of two isoflurane 
anesthetized animals and the sham stimulated animal. The time is counted from the start of the 
experiment. Both the ‘Isoflurane animal 1’(#I4) and the sham stimulated animal show an increase in 
spontaneous activity around 120 minutes after the start of the experiment. In contrast, the ‘Isoflurane 
animal 2’ (#I1) is inactive during the entire procedure.  
 
In order to see if there is a correlation between the BSR and the occurrence of afterdischarges, a 
Pearson’s correlation test was performed within the isoflurane group. The results show correlation in 
2 out of 5 animals (see table 6). 
 
Table 6: Result from the Pearson’s correlation test comparing the BSR with the activity ratio. The 
result indicates a linear correlation in 2 out of 5 isoflurane animals. 
Animal 
R R2 p 
Isoflurane 1 -0,428 0,183 * 
Isoflurane 2 -0,466 0,217 * 
Isoflurane 3 -0,162 0,026 NS 
Isoflurane 4 -0,084 0,007 NS 
Isoflurane 5 -0,322 0,104 NS 
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5.5 Optrode localization 
In order to gain a high response to the light stimulations it was essential to place the optrode at a 
position where there was a high expression of ChR2. There are quite large structural damages along 
the path of the optrode but at the outermost tip of the electrode the tissue is almost intact. All 
optrodes were located in the CA1 region or at the border to the dentate gyrus. Figure 21 and 22 
below show the optrode position in two animals. Intense green correlates to expression of ChR2-
GFP. 
 
Figure 21. Horizontal section of the hippocampus. The arrow indicates where the optrode was 
located. Scale bar: 800 µm. 
 
Figure 22. Coronal section of hippocampus. The arrow shows where the tip of the optrode was 
located. Scale bar: 800 µm. 
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6. Discussion 
In this section, the results from the experiments are discussed in the order they are addressed in 
the results section. Thoughts about how optogenetics can be applied in epilepsy and in other novel 
ways are also presented. As it is not uncontroversial with gene therapy and animal experiments, a 
section with an ethical discussion is included. 
6.1 Evaluating the results 
What is prominent in this project is the individuality in the recordings from the animals. Each animal 
has its own sequence of events and its own characteristics. This is of course expected considering the 
diversity of how individuals respond to drugs [14] and the plasticity of the brain [16].  
What adds to the difficulty in analysing the data is the abundance of artifacts throughout some 
parts of the recordings. These mainly come in two types; breathing artifacts and electronic artifacts. 
The former are related to the in- and exhalation of the animal and is of course dependent on the 
breathing rate and depth. Because of the depressing action isoflurane has on the breathing drive, the 
artifacts coupled to the ventilation in the isoflurane animals is limited, but the ketamine 
anaesthetised animals are heavily affected.  
The breathing artifacts are characterised by periodic broad spectrum peaks in the EEG recording. 
Because of its broad-range frequency components it is difficult to filter them out without losing other 
valuable peaks. It is hard to tell how the artifacts found their way into the recording. One explanation 
could be that it is a slight movement of the ground electrode position or some muscle related electric 
impulse leaking into the electrode. Ketamine anaesthesia, at the dose used, proved unsuitable for 
the optogenetic seizure model since it is crucial to be able to distinguish low amplitude peaks with 
high time resolution. 
The electric artifacts came from large amplitude electrical oscillations interfering with the 
measurements. At some occasions the problem was located to improper grounding, but sometimes 
this large noise seemed to be idiopathic. Luckily, these periods of disturbance are restricted in time 
and were disregarded when analysing the data.  
As seen in figure 13A, some 50 Hz power net oscillations were sometimes visible in the EEG. This 
noise had low amplitude and could be filtered out by the LabChart software, hence not affecting the 
quality of the EEG. 
6.1.1 Test pulses 
Overall, the results of the optogenetic stimulations were robust and good. The Thy1-ChR2 gene 
delivered large depolarisations in response to the short stimulations, with a magnitude of nearly 10 
times the background neural signalling. This indicates that a large population of neurons fired 
simultaneously in response to the blue light in the volume surrounding the optrode tip. There were 
no stimulation artifacts, as there are when using electrical stimulation, which was confirmed by the 
isoelectrical signal obtained during the 593 nm light trains in the sham stimulated animal (data not 
shown). 
The amplitude of the response varied as the optrode was lowered into the tissue. One likely 
explanation is that there are local differences in ChR2-GFP expression, which is confirmed by the 
histological analysis.  
A question that emerges is whether the anaesthetic compound directly interacts with the opsin. 
Since both isoflurane and opsins have their site of action in the cell membrane it is not farfetched 
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that there could be some kind of interaction. Though, in order for ketamine to interfere with the 
opsin, some kind of binding and steric hindrance would be required. The result from the short 
stimulations did not indicate any difference (even if close) between the ketamine and isoflurane 
group considering tissue response. But more studies, designed for the specific cause of finding drug-
opsin interaction, are needed to draw any definitive conclusions. Of course, one challenge with such 
study would be to stimulate the ultimate control group, conscious animals that are not under drug 
influence. 
6.1.2 Stimulation train 
The recordings from the stimulation trains confirm the high speed resolution of the ChR2 [37]. 
These stimulations clearly made such impact on the neurons that afterdischarges were formed in the 
isoflurane group.  
The amplitude of the stimulation spikes decreased during the experiment, as described in both the 
ketamine and isoflurane group. Of course, the animal stimulated with 593 nm light cannot contribute 
to this particular analysis because of the absence of peaks.  
One possible explanation to the amplitude decrease could be exhaustion of the neural tissue. Heavy 
signalling due to the stimulations and/or the time spent under anaesthesia could have impact on the 
neural performance. It is commonly accepted that small animals need support with maintaining body 
temperature during surgery. The high surface to volume ratio and low muscle activity result in a 
temperature drop that might have an impact on CNS metabolism [64]. 
The amplitude level also differed between the animals as seen in figure 13. This could be due to 
tissue damage or different expression level in the vicinity of the optrode tip.  
6.1.3 Afterdischarges  
Much effort has been put into finding the cause of what parameter or parameters that influence 
the development of afterdischarges. It is clear that ketamine, at the given dose, blocks the 
afterdischarges effectively. Since ketamine works as an antagonist on the NMDA receptors [54], one 
can reasonable speculate, that these are involved in the development of afterdischarges. As 
mentioned earlier, ketamine has been reported to end SE. 
The appearance of afterdischarges varied much between the isoflurane animals. In some individuals 
there were very few afterdischarges while one animal developed massive activity lasting for up to 20 
seconds. For example, the peak seen in figure 17 around stimulation nr. 23, is mostly composed of a 
massive increase in afterdischarges in one single animal. The animal was not excluded from this 
analysis in order to point out this diversity in afterdischarge occurrence. What caused these 
fluctuations is not completely clear when reviewing the results. An analysis of linear correlation in 
each isoflurane animal show that there is a very low correlation between the BSR and the 
appearance of afterdischarges in the isoflurane anaesthetised animals. On the other hand, there is a 
trend that the amount of afterdischarges increases with the number of stimulations. This indicate 
that there might be a kindling effect, in contrast to what is recently reported [4].  
6.1.4 Spontaneous events 
As mentioned earlier, the BSR could not be calculated for the ketamine group. The breathing 
artifacts had such magnitude and spectrum that they dominated the recording and overshadowed 
the relatively low magnitude spontaneous events. 
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The results from the isoflurane group on the other hand showed that the amount of spontaneous 
activity gradually increases and decreases in a continuous manner. There is a lot of individuality 
among the animals; some had almost a complete isoelectric baseline during the procedure while 
others had periods where there were more bursts than flat-line.  
One early hypothesis was that the spontaneous events somehow were induced by the stimulation 
trains and represented a kind of inter ictal events. Though, if this were true, the sham stimulated 
animal would have no spontaneous activity, which is not the case (see figure 20). Also, the linear 
correlation analysis comparing the BSR and the afterdischarge occurrence showed very low 
dependence between the variables (see table 6). 
Another possible explanation, which is supported by the literature, is that the spontaneous burst 
pattern is related to the level of sedation [63]. A period of more bursting would then indicate a more 
awake animal. The continuous fluctuations in the BSR could then be related to the adjustments of 
anaesthesia during the experiment or the changing of the heating pad. 
Isoflurane uptake in mice is to some extent self-regulatory since a high dose depresses the 
breathing rate, and the uptake is dependent on the breathing. In an experimental situation the 
breathing rate is monitored and used as an indication of whether to adjust the dose. After the 
adjustment there is latency until the drug has reached an elevated level in the CNS compartment. 
This could explain the continuous variation in the BSR. 
As this project focused on the qualitative aspects of isoflurane versus ketamine anaesthesia there 
are too few data points from the isoflurane dose adjustments to draw any conclusions from the BSR 
dose dependence, even though there is an indication that there is a correlation (data not shown). 
The method for evaluating the BSR could be used in future studies designed to study such dose 
dependence.  
6.1.5 Optrode localisation 
In this project the histological analysis confirmed that the optrode tip was located in the CA1 region. 
Though, it is likely that the response from the tissue is dependent on the particular ChR2-GFP 
expression in the immediate vicinity of the optrode tip. The amount of expression could be assessed 
by studying the intensity of GFP emission from the tissue when examining the samples in the 
microscope. In this case, the preparation of the samples must be exactly the same to be able to 
compare the emission intensities. 
What could be also important is if the optrode tip was introduced immediately over the pyramidal 
cell layer or over an area with processes. The former alternative would yield a better response 
because of the higher density of cells. 
The trauma caused by the insertion of the optrode could also affect the response from the tissue 
and have an impact on the individual variations in the animals. Intact undamaged tissue holds more 
healthy cells that are able of responding to optic stimulation. The amount of damage could, in a 
future assay, be evaluated by immunostaining. 
6.2 Optogenetics and epilepsy 
This work has focused on stimulating neurons to provoke epileptiform activity. There are however 
indications that optogenetics can be used to treat seizures as well [26]. There are multiple subclasses 
of neurons in the hippocampus. Many of these can be targeted using specific promoters and Cre-
LoxP techniques [61]. It is speculated that successful dampening can be achieved either by inhibiting 
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principal cells by NpHR or exciting interneurons using ChR2 [36]. Of course this is closely related to 
the basic research of finding the cause(s) of epilepsy. 
As inhibitory optogenetics have proven to dampen the activity of neurons [65], it is obvious that the 
technique is of interest when searching for novel epilepsy treatments. Ideally, a refined clinical 
solution should have a sensing unit that continuously record EEG data and evaluates it for 
epileptiform activity. If such activity would take place, the optical treatment is to be activated until 
the seizure has ended.  
When analysing EEG data for such on-demand treatments, one must understand that it is 
fluctuating and changing nature depending on the situation. In a healthy person, the brain activity 
varies during different stages of sleep and if the patient is awake different patterns may emerge 
depending on activity [16]. Some physiological patterns even may resemble that of epileptiform 
activity. Hence, there is a need for delicate signal processing if a seizure is to be detected within 
milliseconds. One interesting approach is the use of an artificial neural network (ANN) [66]. These 
networks are capable of recognizing complex patterns in fast manner. The downside, though, is a 
long learning phase which requires time and processing power. Another approach is using 
mathematical methods to evaluate the signal. By combining frequency and peak analysis with logical 
triggers, successful seizure detection and on-demand systems can be constructed [67, 68]. 
Of course, the technical challenges with an implant capable of both detection and intervention are 
enormous. First, there are issues with biocompatibility. Since the implant is to be chronically inserted 
into a sensitive area where there must not be too much scar tissue forming, it is important that the 
device is as small as possible and has material and surface structures that does not alert an 
immunological response. Nanofabrication techniques might contribute to solve this issue.  
In some cases the viral vectors carrying the genetic code for the opsins need to be injected deep 
into the brain tissue. The insertion and retraction of the injection syringe cause trauma to the tissue, 
damaging neurons and blood vessels along its path. Recently it was suggested that an additional 
modality could be added to an optrode [69]. In addition to the possibility to guide light and perform 
electrical stimulation and recordings, a microfluidic channel could be added to the construct. This 
channel is suggested to be used for the initial injection of the vector or form a route for continuous 
administration of drugs in the vicinity of the optrode tip. This would remove the inconvenience of 
retracting the syringe and subsequently inserting the optrode. It is also discussed whether this 
channel could be biodegradable hence minimising the trauma to the brain [69].  
Also, since the penetration of light in brain tissue is limited, the need of an efficient light source is 
obvious. A low power consumption combined with a good light spread is essential to achieve a long 
endurance along with a large therapeutic volume. Current work at this laboratory evaluates utilizing 
nano-leds for this application.  
6.3 Optogenetics and ethics 
Already at the level of the therapeutic application of epilepsy, optogenetics poses ethical questions 
that need to be discussed. Implantation of an optrode in the brain tissue might alter the structure 
and properties of the brain. Also, stimulation with the optrode will change the neural activity in the 
region, hence in theory affecting the very personality of the patient. So in addition to inheriting all 
the controversial aspects coupled to gene therapy, optogenetics also raise the question about how 
much of the human mind that it is acceptable to interfere with. As of today, we are certainly not able 
of reading thoughts, but there is not much stopping us from silencing them.  
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Gene therapy poses numerous ethical questions. A viral infection is irreversible; once the virus has 
infected the cells there is no way to remove the new gene. Also, what kind of genes is it acceptable 
to implant? A patient lacking a gene for producing a vital protein would greatly benefit from having 
gene therapy and people suffering from epilepsy might in the future be helped by optogenetics, but 
is it okay to treat healthy persons with genes coding for exogenous functions? It is necessary to 
debate these questions openly before releasing these powerful tools on any market.  
Many novel medical treatments today need to be tested in animals, both in the developmental 
stage and for examining toxicity. The regulations for animals experiments are strict and focus on 
what is called the three R’s. Refine, reduce and replace. Refinement is about decreasing the amount 
of suffering by optimising the experiment. Reducing means that the amount of animals involved in a 
study must be at a minimum. Finally, replace strive to find other ways, not involving animals, to 
perform the experiment [70]. In the case CNS of related research, there are few replacements for 
animals. Such replacement must mimic the complexity of the interconnectivity of neural tissue and 
that would require reconstructing an entire brain, or at least equivalent circuits. Though, recent 
progress in growing neurological tissue might contribute to solve the problem [71]. 
6.4 Future applications of optogenetics 
Optogenetics shows great potential to become a new revolutionizing technique in bioengineering. It 
reveals a complete new way of interacting with tissue, adding optical light to the arsenal of how to 
manipulate cells.  
Although most applications of optogenetics now are found in neurological tissue it is not farfetched 
to see it implemented in other cell types as well, considering the emerging OptoXRs. Imagine cells 
producing insulin, maybe contained in an implant with semipermeable membranes that release their 
product upon light stimulation. Then it is not unlikely that a closed loop system can be implemented 
which measures the blood glucose levels in real time and adjust the light stimulation frequency or 
intensity inside the implant in respect to the insulin need.  
Another possibility is applications within neuroprosthetics. Imagine a cochlear-implant that, instead 
of sending vibrations to the hair cells, emits a light pattern that relates to the sound signal received 
by an external microphone. If the hair-cells can be modified to express for example 
channelrhodopsin, the light would activate frequency specific neurons with a higher spatial 
resolution than top of the line cochlear implants of today. The use of infrared light to excite neurons 
by heat in a similar manner is currently evaluated [72].  
Much effort is put into combining optogenetics with two-photon (2P) excitation. Since 2P excitation, 
compared to 1P excitation, has the advantage of exciting only the focal plane, it is suggested that the 
technique could be used to target subcellular structures like dendrites and axons in neurons. Also, 
because of the longer wavelengths used, penetration deeper into scattering tissue is possible [73]. It 
might be possible that this method could be utilized in the effort of making communicating contact 
with a single synapse in-vivo. Construction of such device would require the cooperation of many 
disciplines, integrating many fields of technology with medicine and ethics.  
There is an obvious disadvantage using light as basis for cell stimulation in-vivo. Light interacts 
heavily with biomolecules and hence does not propagate far in the tissue. In order to induce a large 
therapeutic volume it might be necessary to utilize multiple light sources which in turn will raise the 
demands on biocompatibility and surgical procedures upon insertion. An alternative could be to 
increase the intensity of one single light source and optimize its scattering. Though, there is a limit of 
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how much light the cells can tolerate in the immediate vicinity of such source without being 
subjected to damage [61].   
To circumvent these problems, one could wish for an external source of stimuli that does not 
interact as strongly with tissue and therefore is not absorbed to the same extent as light. A radio-
frequency (RF) magnetic field is known to heat nano particles consisting of manganese ferrite 
(MnFe2O4). It has been shown that, if coupled to the cell membrane, these particles can open 
temperature sensitive ion channels (TRPV1) when activated by the oscillating field [74]. The raised 
temperature is restricted to the cell membrane and can be induced within seconds of RF activation. 
Similarly to optogenetics, gene therapy has to be used to introduce the temperature sensitive 
channel with high cell type specificity in-vivo. Spatial restriction could be achieved by a stereotactical 
injection. Also, the nanoparticles need to be administered so that they ideally only bind to the cells of 
interest.  
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7. Conclusion and future perspectives 
In this study, transgenic mice were stimulated with an intrahippocampal optrode to produce 
afterdischarges that resemble TLE seizures. The occurrence of electrographical events was detected 
in order to characterize the model. Two types of events were found to occur; spontaneous events 
and afterdischarges. The spontaneous events were not related to the stimulations but rather 
reflected the level of sedation in the mice. Afterdischarges, on the other hand, increased with the 
number of stimulations. The finding that there is a kindling effect in the optogenetically stimulated 
animas stands in contrast to what is previously reported. 
A second aim of the thesis was to investigate whether isoflurane or ketamine/xylazine affects the 
optogenetic seizure model. Afterdischarges were found to occur in the group anesthetised with 
isoflurane but not in the ketamine group. Otherwise there was no difference, considering the tissue 
response, when comparing the two methods. A future, more thorough study of the effect of 
anaesthesia in optogenetical applications should include groups with varying doses of the different 
drugs. In the case of inhaled anaesthetics, it is hard to estimate the concentration in the blood. 
Though, it might be possible to monitor the level of sedation with help of a real time calculation of 
the BSR. Similarly for ketamine, a mathematical model of the metabolism could be utilized to 
calculate the drug concentration in the blood. The results of such experiments could be used to 
optimise the anaesthesia in many types of experiments utilizing optogenetics. 
The final aim of this thesis was to refine the procedure in respect to anaesthetic method and 
optrode position. At the dose used in these experiments, ketamine/xylazine proved unsuitable for 
the optogenetic seizure model. Firstly, it blocks the afterdischarges and prevents the desired 
epileptiform activity to occur. Secondly, the heavy and fast breathing in ketamine anesthetised mice 
overshadows the neural activity of interest. It might be that a lower dose would not have equal 
impact on the afterdischarges. Such a study, comparing different dose levels of ketamine/xylazine, 
could be of essence. Though, when reviewing the result from this study, the use of isoflurane instead 
of ketamine/xylazine is recommended. 
There is more work to be done, considering the optrode position. The coordinates used could be 
evaluated by comparing the histological analysis with a brain atlas. Furthermore, other positions than 
the CA1 region could be considered in order induce afterdischarges more effectively. 
A complicated but interesting experiment would be to stimulate conscious animals. No anaesthesia 
will then interfere with the optogenetic stimulations and there might be more afterdischarges 
developing. Such procedure would require a protocol much alike the one used in electrical kindling; 
the animal must be able to move independently of the cords and optic fibres attached to the 
implanted optrode. Also, similarly to electrical kindling, the optrode will have to be implanted on the 
animal well before the stimulations.  
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